Search
Michigan Paid Clinical Trials
A listing of 2218 clinical trials in Michigan actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1141 - 1152 of 2218
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Location
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Michigan is currently home to 2218 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Ann Arbor, Detroit, Grand Rapids and Kalamazoo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II
Recruiting
To demonstrate the safety and effectiveness of the Shockwave Reducer for treatment of patients with refractory angina pectoris treated with maximally tolerated guideline-directed medical therapy who demonstrate objective evidence of reversible myocardial ischemia in the distribution of the left coronary artery and who are deemed unsuitable for revascularization. A non-randomized single-arm registry will further assess the safety and effectiveness of the Shockwave Reducer in selected subjects wit... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Refractory Angina
JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization
Recruiting
Prospective, randomized, multi-center study designed to evaluate the outcomes of commercially available contemporary EVAR in a real-world population. Patients will be randomized into two device cohorts and compared across the primary endpoints.
Patients will be followed procedurally to discharge, at 1, 6, 12 months and annually through to 5 years (total follow-up commitment).
Gender:
ALL
Ages:
21 years and above
Trial Updated:
06/05/2025
Locations: Henry Ford Hospital, Detroit, Michigan
Conditions: AAA, AAA - Abdominal Aortic Aneurysm
Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial
Recruiting
The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 180 days as measured by the Modified Rankin Score (m... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/05/2025
Locations: Henry Ford Hospital, Detroit, Michigan
Conditions: Intracerebral Hemorrhage
The Cancer of the Pancreas Screening-5 CAPS5)Study
Recruiting
Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Pancreas Cancer, Peutz-Jeghers Syndrome (PJS), Gene Mutation, Germline Mutation Carrier, Lynch Syndrome
A Trial to Test the Safety and Efficacy of TEV-53408 in Treating Vitiligo
Recruiting
The primary objective of the trial is to evaluate the safety of TEV-53408 administered subcutaneously for the treatment of adults with vitiligo.
A secondary objective is to further evaluate the safety of TEV-53408.
The planned study period per participant is 84 weeks including a screening period (up to 4 weeks), a 24-week open-label treatment period, a 16-week washout period, and a 40-week follow-up period.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/04/2025
Locations: Teva Investigational Site 12048, Canton, Michigan
Conditions: Vitiligo
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Recruiting
This phase I/II tests the safety, side effects and best dose of ruxolitinib in combination with enzalutamide and how well it works in treating patients with prostate cancer that remains despite blocking hormone production (castration-resistant) and that has spread from where it first started to other places in the body (metastatic). Ruxolitinib, a kinase inhibitor, slows down the growth of the tumor by blocking the proteins, JAK1 and JAK2, tumors use to grow. Enzalutamide, an androgen receptor i... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Recruiting
The study will assess the efficacy and safety of pegozafermin administered in participants with compensated cirrhosis due to MASH (biopsy-confirmed fibrosis stage F4 MASH \[previously known as nonalcoholic steatohepatitis, NASH\]).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/04/2025
Locations: 89bio Clinical Study Site, Ann Arbor, Michigan
Conditions: Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
Recruiting
This study will evaluate the efficacy and safety of Armour Thyroid treatment compared with synthetic T4 in subjects who have primary hypothyroidism and are currently stabilized (i.e., in-range thyroid-stimulating hormone \[TSH\]) on synthetic T4 treatment. This study will also therefore evaluate the efficacy and safety of dose conversion from synthetic T4 therapy to Armour Thyroid therapy.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/04/2025
Locations: Metro Detroit Endocrinology Center /ID# 260862, Dearborn, Michigan
Conditions: Hypothyroidism
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration
Recruiting
The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with nAMD.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/04/2025
Locations: Associated Retinal Consultants (ARC) P.C. - Opthalmology, Royal Oak, Michigan
Conditions: Neovascular Age-Related Macular Degeneration (nAMD)
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Recruiting
The study consists of two parts: Part 1 The primary purpose of this part aims to evaluate the safety, tolerability, and clinical activity of escalating doses of single agent belantamab in participants with refractory multiple myeloma (RRMM) who have received at least 3 prior therapies (4L+). Part 2 The primary purpose of this part is to evaluate the safety, tolerability, and clinical activity of different dose ratios of belantamab mafodotin in combination with belantamab (delivered as separate d... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: GSK Investigational Site, Grand Rapids, Michigan
Conditions: Multiple Myeloma
Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma
Recruiting
The purpose of this study is to see if Isatuximab can alter the immune system in patients with multiple myeloma or lymphoma upon recovery from the autologous stem cell transplantation. The investigators will see if Isatuximab makes changes to the immune system so that upon recovery from the transplant, the immune system can fight the cancer. This study will have two arms. On one arm (control arm), participants will receive standard transplant procedures and on the other arm (experimental arm), p... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: Karmanos Cancer Institute, Detroit, Michigan
Conditions: Lymphoma, Multiple Myeloma, Non-Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult
Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study
Recruiting
Prospective, randomized, open-label, international, multi-center clinical study to evaluate the safety and efficacy of the AccuCinch Ventricular Restoration System in patients with heart failure and reduced ejection fraction (HFrEF).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Heart Failure With Reduced Ejection Fraction (HFrEF), Dilated Cardiomyopathy
1141 - 1152 of 2218
Clinical trials vary in time; in total a single clinical trial may take up to 15 years to complete, and some longitudinal studies ask the participant to stay in touch for follow up questions for a few years after their participation in the study is finished. Depending on the goal and the design of a clinical trial, volunteers may be asked to stay on site for a set amount of nights; this happens because the researchers might want to monitor the participant's at different hours of the day or night. Some clinical research is also setup to compensate individuals, and paid clinical trials are not uncommon.
In Michigan, the University of Michigan division of research has one of the largest clinical trial and research centers in the state, where interested volunteers can enroll in studies for healthy or non-healthy individuals. The Barbara Ann Karmanos cancer institute in Detroit, Michigan also offers clinical trials for many types of cancers for both healthy and non-healthy individuals.
Volunteers who decide to participate in a clinical trial may be compensated for their time and travel expenses during their participation in the study. The compensation will vary depending on the type of study and level of participation required from the volunteer, but paid clinical trials in Michigan are very common.
Participating in a clinical trial is always completely voluntary. This means that nobody, regardless of their condition can be forced to participate nor can they be forced to continue participating in a trial if they wish to withdraw from the study. Non-healthy individuals who decide to enroll in a clinical trial after a suggestion from their doctor or to try an experimental treatment for their condition will never be denied care if they decide to drop out of the study.
Search Clinical Trials in Michigan by Condition
See All Conditions